Agree, it is not out of the question and politics matter. If a strong additional analysis shows efficacy then it is not a leap to move forward with recognition. When one considers what AD is and the dynamics of demonstrated A2-73 safety performance along with other pre clinical trial evidence the requirements appear to be met. Many unknowns of course.
News 
Market Data 
Discover 
